Adverts

Open Access Articles- Top Results for Bendroflumethiazide

Bendroflumethiazide

</th></tr></th></tr>
Bendroflumethiazide
File:Bendroflumethiazide.svg
File:Bendroflumethiazide-3D-vdW.png
Systematic (IUPAC) name
3-Benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4- benzothiadiazine-7-sulfonamide
Clinical data
AHFS/Drugs.com Consumer Drug Information
Oral
Pharmacokinetic data
Bioavailability 100%
Protein binding 96%
Metabolism extensive
Half-life 3-4 hours[2]
Identifiers
73-48-3 7pxY
C03AA01
PubChem CID 2315
DrugBank DB00436 7pxY
ChemSpider 2225 7pxY
UNII 5Q52X6ICJI 7pxY
KEGG D00650 7pxY
ChEBI CHEBI:3013 7pxY
ChEMBL CHEMBL1684 7pxY
Chemical data
Formula C15H14F3N3O4S2
421.415 g/mol
 14pxY (what is this?)  (verify)

Bendroflumethiazide (INN), formerly bendrofluazide (BAN), trade name Aprinox, is a thiazide diuretic used to treat hypertension.

Bendroflumethiazide is a thiazide diuretic which works by inhibiting sodium reabsorption at the beginning of the distal convoluted tubule (DCT). Water is lost as a result of more sodium reaching the collecting ducts. Bendroflumethiazide has a role in the treatment of mild heart failure although loop diuretics are better for reducing overload. The main use of bendroflumethiazide currently is in hypertension (part of the effect is due to vasodilation).

Common adverse effects:[medical citation needed]

Rare adverse effects:[medical citation needed]

References

  1. BNF 45 March 2003
  2. Ed. Sean C. Sweetman (ed.). Martindale: The complete drug reference (33 ed.). Pharmaceutical Press.